吡咯替尼联合TP方案治疗乳腺癌的临床疗效

doi:10.3969/j.issn.1671-7171.2025.05.018

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1165 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the efficacy of pyrotinib combined with the TP regimen (paclitaxel plus cisplatin) in the treatment of breast cancer patients.【Methods】 A total of 100 breast cancer patients were divided into the control group and the observation group based on different treatment regimens, with 50 cases in each group. The control group received the TP regimen, while the observation group was treated with pyrotinib combined with the TP regimen. The clinical application effects of different treatment regimens were compared between the two groups.【Results】 The disease control rate, post-treatment serum microRNA-22-3P (miR-22-3P) level, immune indicators CD4⁺, CD4⁺/CD8⁺ ratio, progression-free survival, and overall survival in the observation group were all higher than those in the control group (P<0.05). Meanwhile, the post-treatment cysteine-rich protein 61 (CYR61) level and CD8⁺ level in the observation group were lower than those in the control group (P<0.05).【Conclusion】 Pyrotinib combined with the TP regimen for breast cancer treatment can effectively increase serum miR-22-3P level, reduce CYR61 level, continuously improve immune function, prolong progression-free survival and overall survival, and it has good safety.

Key words： Breast Neoplasms Antineoplastic Combined Chemotherapy Protocols Treatment Outcome

Received: 01 August 2024

PACS:

R737.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Yushuai
	YUE Saichao

Cite this article:

SHI Yushuai,YUE Saichao. Clinical Efficacy of Pyrotinib Combined with TP Regimen in the Treatment of Breast Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 799-801.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.05.018 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I5/799

[1] 向云飞,苏飞,杨景茹,等.吡咯替尼联合化疗新辅助治疗HER2阳性早期或局部晚期乳腺癌的临床研究[J].兰州大学学报(医学版),2022,48(7):77-81.
[2] 祝洪梅,项海芝,宁纯民.SOX和TP方案治疗晚期三阴性乳腺癌的临床疗效及生存情况的比较[J].癌症进展,2019,17(2):169-172.
[3] 张恒乐,董雪珂,殷雨来,等.三阴性乳腺癌TP方案新辅助化疗疗效及预后因素分析[J].中国新药与临床杂志,2023,42(10):664-669.
[4] 任文静,张婉璐,王慧冰,等.吡咯替尼治疗HER2阳性乳腺癌的疗效和安全性[J].中国药物应用与监测,2023,20(1):5-9.
[5] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679.
[6] SCHWARTZ L H,SEYMOUR L,LITIERE S,et al.RECIST 1.1-Stan-dardisation and disease-specific adaptations:Perspectives from the RECIST Working Group[J].Eur J Cancer,2016,62(33):138-145.
[7] 王琳,陈在余.吡咯替尼联合卡培他滨二线治疗HER-2阳性晚期乳腺癌的药物经济学评价[J].中国药房,2022,33(13):1624-1629.
[8] 杨涛,马秀芬,毛红岩,等.TP与EC-T化疗方案在三阴性乳腺癌新辅助化疗中疗效与BRCA1突变关系[J].现代肿瘤医学,2022,30(10):1776-1780.
[9] 郭书坤,徐艳蕾,袁超,等.TP方案在三阴性乳腺癌新辅助化疗中的疗效及预后分析[J].现代肿瘤医学,2020,28(11):1874-1877.
[10] 陈淑如,方勤,陈晓越.2种新辅助化疗方案对可手术三阴性乳腺癌的临床疗效及其与BRCA1基因的相关性研究[J].中国现代应用药学,2020,37(24):3009-3013.
[11] 千维娜,李治,李仁廷,等.西黄丸联合TP方案治疗中晚期乳腺癌效果分析[J].辽宁中医杂志,2020,47(6):115-117.
[12] 周守兵,刘宇,刘虎,等.吡咯替尼联合化疗在曲妥珠单抗耐药乳腺癌肝转移患者中的疗效[J].安徽医学,2020,41(1):33.
[13] 薛昭,孙刚.吡咯替尼靶向治疗乳腺癌对患者血清中Hcy、CA153、FA的影响研究[J].贵州医药,2023,47(8):1207-1209.
[14] 赵晓宇,宋忠花,曲向晖.吡咯替尼联合化疗治疗晚期HER2阳性乳腺癌的疗效[J].医学临床研究,2022,39(2):205-207.